**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 69841

**Manuscript Type:** CASE REPORT

**Isolated coagulopathy without classic CRAB symptoms as the initial manifestation of multiple myeloma: A case report**

Zhang Y *et al*. Myeloma case presenting coagulopathy initially

Ya Zhang, Fang Xu, Jing-Jing Wen, Lin Shi, Qiao-Lin Zhou

**Ya Zhang, Fang Xu, Jing-Jing Wen, Lin Shi, Qiao-Lin Zhou,** Department of Hematology, Mianyang Central Hospital, Mianyang 621000, Sichuan Province, China

**Author contributions:** Zhang Y and Fang Xu F contributed equally to this work; Zhang Y and Xu F designed the study; Zhang Y and Wen JJ collected the data; Zhang Y and Xu F analyzed the data; Zhang Y, Xu F, and Wen JJ interpreted the data; Zhang Y, Xu F, Wen JJ and Shi L prepared the manuscript; Shi L and Zhou QL searched and reviewed the literature.

**Corresponding author: Fang Xu, MD, Academic Fellow, Chief Doctor,** Department of Hematology, Mianyang Central Hospital, No. 12 Changjia Alley, Jingzhong Street, Fucheng District, Mianyang 621000, Sichuan Province, China. 147377807@qq.com

**Received:** July 13, 2021

**Revised:** December 1, 2021

**Accepted:** March 4, 2022

**Published online:** April 26, 2022

**Abstract**

BACKGROUND

Multiple myeloma patients usually present with CRAB symptoms (hypercalcemia, renal disease, anemia and bone diseases) as initial manifestations. Bleeding symptoms are less common, most of which result from thrombocytopenia or infiltration of plasmacytoma. Relatively, coagulopathy is not so common, especially isolated coagulopathy without CRAB manifestations, which is very rare. Herein, we report a 54-year old female who was hospitalized for intermittent and recurrent mild oral mucosal hemorrhage without other bleeding symptoms for almost one month or typical myeloma features.

CASE SUMMARY

Two months before admission, the patient underwent implantation of a permanent pacemaker due to sick sinus syndrome. Prothrombin time and activated partial thromboplastin time were significantly prolonged. Factor X deficiency was demonstrated to account for the coagulation dysfunction. An M protein peak was shown by serum protein electrophoresis. 26.11% of abnormal plasma cells were detected in bone marrow by flow cytometry, expressing CD38, CD138, CD56 and intracellular immunoglobulin Kappa light chain. Bone marrow biopsy also proved the presence of abnormal plasma cells, but Congo red stain was negative. The patient was finally diagnosed with multiple myeloma IgA-κ type. A literature review indicated that factor X deficiency was highly related to amyloidosis. Before bleeding signs, the patient had cardiac arrhythmia, enlargement of the heart, and progressive heart failure; thus, cardiac amyloidosis was suspected.

CONCLUSION

Bleeding related to coagulation dysfunction is uncommon in multiple myeloma, especially as the initial manifestation. Amyloidosis is a well-recognized cause of isolated acquired factor X deficiency.

**Key Words:** Multiple myeloma; Coagulation function; Hemorrhage; Factor X; Deficiency; Case report

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Zhang Y, Xu F, Wen JJ, Shi L, Zhou QL. Isolated coagulopathy without classic CRAB symptoms as the initial manifestation of multiple myeloma: A case report and literature review. *World J Clin Cases* 2022; 10(12): 3822-3827

**URL:** https://www.wjgnet.com/2307-8960/full/v10/i12/3822.htm

**DOI:** https://dx.doi.org/10.12998/wjcc.v10.i12.3822

**Core Tip:** Coagulopathy resulting from isolated acquired factorⅩ deficiency is uncommon in myeloma. Typical symptoms in multiple myeloma include hypercalcemia, renal disease, anemia and bone diseases (CRAB). Factor Ⅹ deficiency could herald the CRAB symptoms, and was reported to be closely related to amyloidosis. Secondary amyloidosis could be reasonably suspected if factor Ⅹ deficiency is verified in myeloma patient.

**INTRODUCTION**

Multiple myeloma is one of the most common hematological malignancies. Usually myeloma patients initially present with CRAB symptoms (hypercalcemia, renal disease, anemia and bone diseases). As reported, bleeding occurs in almost 7% of *de novo* myeloma patients[1], often combined with CRAB symptoms. Thrombocytopenia and infiltration of plasmacytoma account for most bleeding events. Coagulopathy is not common, especially isolated coagulopathy without CRAB manifestations, which is very rare. Herein, we report a multiple myeloma patient presenting with recurrent bleeding of oral mucosa and coagulopathy as initial manifestations without typical myeloma features.

**CASE PRESENTATION**

***Chief complaints***

A 54-year old female was hospitalized for intermittent and recurrent mild oral mucosal hemorrhage without other bleeding symptoms for almost one month.

***History of present illness***

Initially, the patient presented no weakness, oliguria, edema, bone pain, *etc*. Drug abuse, and contact with rodenticide and other toxic agents was denied. Coagulation function was assessed two weeks before admission during her first visit to the Hematology Outpatient Department. Prothrombin time (PT) and activated partial thromboplastin time (APTT) were significantly prolonged, and were 20.7 s and 41 s, respectively. Fibrinogen was 1.79 g/L and thrombin time was normal. D dimer and fibrin degradation products were higher than the normal level, and were 6.2 mg/L and 2.29 mg/L, respectively. Considering the prolongation of both PT and APTT, vitamin K1 was administered at 40 to 80 mg/d. Bleeding seemed to initially improve slightly but recurred and became more obvious and frequent. PT and APTT were still longer than normal. The patient also had a cough and expectoration. She was admitted for further investigation and diagnosis.

***History of past illness***

Past history indicated that the patient was a hepatitis B virus carrier. Two months before admission, she underwent implantation of a permanent pacemaker due to sick sinus syndrome in another hospital. Before and after the operation, routine blood tests and laboratory examinations were normal, and PT was 15.7 s. The patient denied taking any other drugs except atorvastatin calcium after discharge.

***Personal and family history***

The patient denied having personal and family history.

***Physical examination***

On admission, several oral blood blisters and spontaneous gingival bleeding were noted. No petechiae, ecchymoses or purpura were observed on the skin. Some wet rales were heard on both sides of the lungs. The heart boundary was enlarged. No splenomegaly, hepatomegaly or masses were found in the abdomen.

***Laboratory examinations***

Laboratory examinations showed that the level of factor Ⅱ, factor Ⅷ and factor Ⅸ were normal, but factor Ⅹ level was 9.8%. PT delay could be corrected once fresh frozen plasma was used. Routine blood tests revealed normal white blood cell (WBC) count, hemoglobin of 10.7 g/L and platelets of 90x109/L. Brain natriuretic peptide was 5966 ng/L (normal range < 125 ng/L). Immunoglobulin (Ig)A level was 17.6 g/L, significantly higher than normal (range 1.0-4.2 g/L), while IgG, IgE, and IgM were lower than the normal level. β2 microglobulin was 4.836 mg/L (normal range 0.9-2.0 mg/L). Blood immunofixation electrophoresis verified the existence of monoclonal immunoglobulin, which was IgA-κ type. An M protein peak was shown by serum protein electrophoresis. M protein was 11.26 g/L. Liver function indicated a mild to moderate increase in liver enzymes, including alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase and alkaline phosphatase. Renal function tests showed that creatinine was 67 μmol/L, uric acid was 366.5 μmol/L, and the glomerular filtration rate was 45.9 mL/min.

***Imaging examinations***

A low dose computed tomography (CT) scan of the whole body did not find any obvious osteolytic lesions. A CT scan and color Doppler ultrasound both indicated enlargement of the heart, especially both atria. Moderate tricuspid regurgitation, mild mitral regurgitation, widened pulmonary artery diameter, mild pulmonary hypertension, a slightly thicker ventricular septum, and mild pericardial effusion were also noted.

***Further diagnostic work-up***

26.11% of plasma cells were detected in bone marrow by flow cytometry, expressing CD38, CD138, CD56 and intracellular immunoglobulin Kappa light chain. The expression of CD38 and CD138 indicated that the abnormal cells were originated from plasma cells. Restricted expression of intracellular immunoglobulin Kappa light chain suggested they were clonal plasma cells. CD56 expression further proved that they were abnormal and neoplastic plasma cells. Bone marrow biopsy also proved the existence of abnormal plasma cells, but Congo red stain was negative.

**FINAL DIAGNOSIS**

Multiple myeloma (IgA-κ type); acquired factor Ⅹ deficiency; And sick sinus syndrome.

**TREATMENT**

The patient started the first cycle of chemotherapy including bortezomib (1.3 mg/m2, weekly) and dexamethasone (20 mg, weekly) as soon as the myeloma diagnosis was established.

**OUTCOME AND FOLLOW-UP**

Unfortunately, the patient died of heart failure during the first cycle of chemotherapy in the third week.

**DISCUSSION**

Multiple myeloma is usually characterized by CRAB symptoms. Bleeding is relatively uncommon in myeloma patients. As reported in a retrospective study[1], the incidence of hemorrhage is 7% in myeloma patients. Men appear to be more affected than women[2-6], most of whom are middle-aged and elderly patients (Table 1). In terms of bleeding sites, not only skin and mucosa[1-4,7] but also deep vital organs[8-12] including the gastrointestinal tract, respiratory tract, brain, *etc* can be involved. Hemorrhagic symptoms can also manifest spontaneously or postoperatively[13-14], occur in isolated sites or multiple sites. With regard to Ig type, a literature review indicated that myeloma patients with IgA type were inclined to bleed[9-10,12,15]. This patient was also IgA-κ type.

The causes of bleeding in myeloma patients are mainly related to thrombocytopenia, hematopoietic failure due to infiltration of plasma cells or hyperviscosity syndrome. Patients rarely present with bleeding symptoms or coagulopathy alone. Our patient initially only presented with recurrent bleeding of oral mucosa and abnormal coagulation function. Factor X deficiency accounted for her coagulopathy. As the disease progressed, immunoglobulinemia, mild anemia, pneumonia, and heart failure were noted. The diagnosis of IgA-κ type multiple myeloma was finally confirmed by bone marrow tests and immunofixation electrophoresis.

The main mechanism of coagulation dysfunction in myeloma is believed to involve excessive immunoglobulins which affect coagulation factors, platelets, or fibrinogen, forming protein complexes. These complexes further lead to secondary deficiency of coagulation factors and hemorrhagic symptoms[7,11-12]. Factor Ⅱ, Ⅶ, Ⅷ, Ⅹ, Ⅺ, Ⅻ, von WΧgen deficiency have been reported in myeloma patients[2-3,16]. As reported, isolated acquired FⅩ deficiency mostly occurs in amyloidosis, and is not so common in myeloma[16-18] (Table 1). In the largest clinical study on acquired FactorⅩdeficiency and amyloidosis, of 368 consecutive patients with systemic light chain amyloidosis, 32 patients (8.7%) had factor X levels lower than 50% of the normal level. Eighteen of these patients (56%) had bleeding complications, which were more frequent and severe in the 12 patients who had factor X levels lower than 25% of the normal level[18]. Earlier studies indicated that the incidence of factor X deficiency in patients with amyloidosis was 6.3% to 14%[19]. With the exception of amyloidosis, isolated acquired factor X deficiency has seldom been reported in other diseases[20]. In this case, we failed to prove the existence of secondary amyloidosis. Before bleeding signs, the patient had cardiac arrhythmia, enlargement of the heart, and progressive heart failure; thus, cardiac amyloidosis was highly suspected. However, this was not proved as a cardiac muscle biopsy was difficult to obtain. Whether isolated acquired factor X deficiency can predict amyloidosis is worth further study.

**CONCLUSION**

Bleeding related to coagulation dysfunction is uncommon in multiple myeloma, especially as the initial manifestation. However, coagulopathy may still be the main complaint in myeloma patients. Many coagulation factors and coagulation inhibitors could be involved in myeloma including factor Ⅹ. Amyloidosis is a well-recognized cause of isolated acquired factor Ⅹ deficiency. Whether isolated acquired factor Ⅹdeficiency can predict the presence of amyloidosis requires further investigation.

**REFERENCES**

1 **Kyle RA**. Multiple myeloma: review of 869 cases. *Mayo Clin Proc* 1975; **50**: 29-40 [PMID: 1110582 DOI: 10.1016/S0140-6736(75)91552-4]

2 **Zou Lifang**, Hu Junpei, Ye Weide. A Clinical Study of Hemostatic Abnormality in Multiple Myeloma Patients. *Xue Shuan Yu Zhi Xue Xue* 2002; **8**: 118-120

3 **Zeng Manni**. Coagulation factors in patients with multiple myeloma research. *Zhonghua Jian kang Wen Zhai* 2013; 18-19

4 **Xie Weicheng**, Li Juan, Zhang Guocai, Luo shaokai. Clinical features of 358 cases multiple myeloma. *Xin Yi Xue* 2002; **33**: 160-161

5 **Zhuang Junling**, Wu Yongji, Zhong Yuping, He Jian, Shen Ti, Zhang Zhinan. Clinical features of 218 cases multiple myeloma. *Zhongguo Shi Yong Nei KeZaZhi* 2004; **24**: 108-110 [DOI: 10.3969/j.issn.1005-2194.2004.02.025]

6 **Zhang Jun**, Deng Hongyu, Wu Gang, Li Shuangqing. Clinical analysis of 148 cases of multiple myeloma. *Clinical Focus* 2005; **20**: 452-454 [DOI: 10.3969/j.issn.1004-583X.2005.08.014]

7 **Li Hongmei**, Wang Yongjun. Clinical analysis of Multiple myeloma with hemorrhage of digestive tract as initial manifestations. *J Clini and Experi Med* 2016; **15**: 2265-2267 [DOI: 10.3969/j.issn.1671-4695.2016.22.030]

8 **Hobbs JG**, Van Slambrouck C, Miller JL, Yamini B. Intracranial hemorrhage as initial manifestation of plasma cell myeloma: A case report. *J Clin Neurosci* 2018; **50**: 133-135 [PMID: 29428262 DOI: 10.1016/j.jocn.2018.01.054]

9 **Kawashima I**, Takano K, Kumagai T, Koshiishi M, Oishi S, Sueki Y, Nakajima K, Mitsumori T, Kirito K. Combined Coagulopathy Can Induce Both Hemorrhagic and Thrombotic Complications in Multiple Myeloma. *Intern Med* 2018; **57**: 3303-3306 [PMID: 29984746 DOI: 10.2169/internalmedicine.0915-18]

10 **Furube A**, Kagiyama N, Ishiguro T, Takaku Y, Kurashima K, Shimizu Y, Takayanagi N. Diffuse alveolar hemorrhage caused by IgA deposition associated with multiple myeloma. *Clin Case Rep* 2019; **7**: 1049-1052 [PMID: 31110743 DOI: 10.1002/ccr3.2151]

11 **Sun Mingli**, Song Jie, Li Xueyong, Li Yunzhi. Multiple myeloma with special manifestations. *J of Leu & Lym* 2007; **16**: 297-298 [DOI: 10.3760/cma.j.issn.1009-9921.2007.04.023]

12 **Zhang Xia**, Wang Weiwei, Guo Jinjing, Huang Chuanrong, Wang Weiguo. Clinical significance of von Willebrand factor, D-dimer and AT-Ⅲ in multiple myeloma. *Anhui Med J* 2018; **39**: 456-458 [DOI: 10.3969/j.issn.1000-0399.2018.04.022]

13 **Sari I**, Erkurt MA, Ifran A, Kaptan K, Beyan C. Multiple myeloma presenting with acquired factor VIII inhibitor. *Int J Hematol* 2009; **90**: 166-169 [PMID: 19551464 DOI: 10.1007/s12185-009-0363-9]

14 **Dicke C**, Schneppenheim S, Holstein K, Spath B, Bokemeyer C, Dittmer R, Budde U, Langer F. Distinct mechanisms account for acquired von Willebrand syndrome in plasma cell dyscrasias. *Ann Hematol* 2016; **95**: 945-957 [PMID: 27040683 DOI: 10.1007/s00277-016-2650-x]

15 **Richard C**, Cuadrado MA, Prieto M, Batlle J, López Fernández MF, Rodriguez Salazar ML, Bello C, Recio M, Santoro T, Gomez Casares MT. Acquired von Willebrand disease in multiple myeloma secondary to absorption of von Willebrand factor by plasma cells. *Am J Hematol* 1990; **35**: 114-117 [PMID: 2205095 DOI: 10.1002/ajh.2830350210]

16 **Liu W**, Xuan M, Xue F, Yang R. Acquired coagulation factor X deficiency: three cases report and literature review. *Zhonghua Xue Ye Xue Za Zhi* 2014; **35**: 633-636 [PMID: 25052608 DOI: 10.3760/cma.j.issn.0253-2727.2014.07.014]

17 **Furie B**, Greene E, Furie BC. Syndrome of acquired factor X deficiency and systemic amyloidosis in vivo studies of the metabolic fate of factor X. *N Engl J Med* 1977; **297**: 81-85 [PMID: 865580 DOI: 10.1056/NEJM197707142970203]

18 **Choufani EB**, Sanchorawala V, Ernst T, Quillen K, Skinner M, Wright DG, Seldin DC. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding manifestations, and response to high-dose chemotherapy. *Blood* 2001; **97**: 1885-1887 [PMID: 11238135 DOI: 10.1182/blood.V97.6.1885]

19 **Mumford AD**, O'Donnell J, Gillmore JD, Manning RA, Hawkins PN, Laffan M. Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. *Br J Haematol* 2000; **110**: 454-460 [PMID: 10971408 DOI: 10.1046/j.1365-2141.2000.02183.x]

20 **Boudin L**, Patient M, Roméo E, Bladé JS, Gisserot O, de Jauréguiberry JP. Acquired, non-amyloid related factor X deficiency: A first case associated with atypical chronic lymphocytic leukemia and literature review. *Rev Med Interne* 2017; **38**: 478-481 [PMID: 28110969 DOI: 10.1016/j.revmed.2016.12.003]

**Footnotes**

**Informed consent statement:** Informed written consent was obtained from the patient for publication of this report.

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** July 13, 2021

**First decision:** November 22, 2021

**Article in press:** March 4, 2022

**Specialty type:** Hematology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Haque N, Bangladesh **S-Editor:** Ma YJ **L-Editor:** A **P-Editor:** Ma YJ

**Table 1 Summary of clinical features in patients with multiple myeloma with bleeding symptoms**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Number of bleeding cases/total cases** | **Gender (*n*)** | **Median/average age (yr)** | **Types of M protein (%)** | **Amyloidosis (*n*)** | **Bleeding sites** | **APTT** | **PT** | **TT** | **FIB** | **Involved coagulation factors (*n*)** |
| Kyle[1], China, 2014 | 3 | Male (3) | 57 | NS | Yes | Skin; Mucous | Prolonged | Prolonged | Prolonged | N | Ⅹ |
| Zou *et al*[2], China, 2002 | 44636 | Male (9); Female (7) | 68.9 (average) | IgG (87.5); IgA (6.25); IgD (6.25) | NS | Skin; Nasal mucosa; Gingiva | NS | NS | NS | NS | Ⅰ, Ⅶ, Ⅹ, Fbg |
| Zeng *et al*[3], China, 2013 | 44772 | Male (16); Female (14) | 60 ± 10 (average) | IgG (90); IgA (6.7);  IgD (3.3) | NS | Skin; Nasal mucosa; Gingiva (7) | NS | NS | NS | NS | Ⅱ, Ⅷ |
| Xie *et al*[4], China, 2002 | 12/358 | Male (208); Female (150) | 55 (median) | NS | NS | Skin; Nasal mucosa; Gingiva (12) | NS | NS | NS | NS | NS |
| Zhuang *et al*[5], China, 2004 | 20/218 | Male (136); Female (82) | 57 (average) | IgG (45.3); IgA (18.4); IgD (11.7); IgM (0.6%); κ (11.2); λ (9.5); No secretion (2.2); bi-clone (1.1) | Yes (18) | NS | NS | NS | NS | NS | NS |
| Zhang *et al*[6], China, 2005 | 30/148 | Male (98); Female (50) | 58 (average) | Heavy chain types; IgG (44.7); IgA (22.0); IgM (2); No secretion (31.7); Light chain types; κ (47.7%); λ (52.3%) | NS | Nasal mucosa (17); Gingiva (7); Melena (6); Hematuria, fundus hemorrhage, gingiva | NS | NS | NS | NS | NS |
| Sari *et al*[13], Japan, 2008 | 1 | Female | 43 | IgG | NS | Post operation of ovarian cyst | Prolonged | NS | NS | NS | Ⅷ |
| Dicke *et al*[14], China, 2016 | 1 | Male | 63 | IgG | NS | Post operation of orthodontics | Prolonged | NS | NS | 1.8g/l | vWF:Ac |
| Hobbs *et al*[8], USA, 2019 | 1 | Male | 59 | NS | NS | Gastrointestinal tract | Prolonged | prolonged | NS | NS | Ⅹ |
| Kawashima *et al*[9], Japan, 2018 | 1 | Male | 52 | IgA | NS | Thigh muscle, hematuria | Prolonged | N | NS | NS | Ⅷ, vWF |
| Furube *et al*[10], Japan, 2018 | 1 | Male | 77 | IgA | NS | lung | Prolonged | prolonged | NS | NS | NS |
| Richard *et al*[15], USA, 1990 | 1 | Female | 67 | IgA | NS | Melena | Prolonged | N | N | NS | Ⅷ, vWF |
| Li *et al*[7], England, 1977 | 1 | Male | 49 | NS | Yes | Mucosa | Prolonged | Prolonged | Prolonged | low | Ⅹ |
| Sun *et al*[11], USA, 2001 | 18/368 | Male (221); Female (147) | 58 | NS | Yes | Gastrointestinal tract, hematuria, skin, spleen, abdomen | Prolonged | NS | NS | NS | Ⅹ(32) |
| Zhang *et al*[12], USA, 2018 | 1 | Male | 48 | IgA | NS | intracranial | NS | NS | NS | NS | NS |

NS: No significance; N: Normal; κ: Kappa; λ: Lambda; APTT: Activated partial thromboplastin time; PT: Prothrombin time; TT: Thrombin time; FIB Fibrinogen.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**